Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A
Status:
Completed
Trial end date:
2020-05-27
Target enrollment:
Participant gender:
Summary
The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the
substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a
major role in chronic inflammation that is typical in RA. This study investigates the drug
FB704A, which is believed to lower the inflammation caused by IL-6. This study will be in 2
sequential parts: a single increasing dose part (Part 1) and a multiple-increasing dose part
(Part 2). Subjects will receive either active or placebo drug by IV infusion. Subjects in
both parts will have a short stay in the clinic at the start of the study, then will return
for outpatient visits.